Three major problems of Chinese pharmaceutical industry

Source: Tan Yong, Sohu Health 2011-12-21 [author profile], executive editor of medical manager magazine [main point of view] policy becomes the way for policy makers to gain the official career of bureaucrats; the whole Chinese pharmaceutical industry is cheated by capital, and after 100 billion capital enters the industry, it does not promote the product innovation to a new height; how many thoughts and values the pharmaceutical entrepreneurs output to the public directly determines whether the industry can be born into a large enterprise These three problems are not only the problems of last year and this year, but also the problems of tomorrow and the next year They are the core problems that Chinese pharmaceutical enterprises must face for their sustainable development To raise these three questions is our explanation to the Chinese pharmaceutical industry in 2011, which is coming to an end The first is that some industrial policies marked by "bidding" are absurd and childish The persistent problem lies in the fact that policy makers are "false only, real only, not real" Policy has become a way for policy makers to obtain bureaucratic career, rather than solving practical problems In almost every day's forums in the pharmaceutical industry, you can always hear complaints, anger and helplessness from experts and entrepreneurs Three years of the new medical reform, not to mention the random increase of the list of basic drugs, and discussed the zero difference rate of one year From the original purpose of the reform, it is absolutely not necessary for CCTV news broadcast to let you know whether such things as expensive medical treatment for ordinary residents can be alleviated, but everyone can see them personally The second is that the whole Chinese pharmaceutical industry has been cheated by capital: after entering the Chinese pharmaceutical industry, 100 billion capital has not raised the product innovation of the pharmaceutical industry to a new level Those high-quality enterprises that do not lack money and do not need money are full of PE like migrant workers In addition to money, the biggest skill of these barbarians at the gate is that they may find leaders of a certain province to greet entrepreneurs and let themselves in A big joke in the investment community is that Zhejiang Beida pharmaceutical industry, which was fried as the birth of "two bombs and one star" in the pharmaceutical industry this year, was chased by all kinds of PE crazily Only last year, it was only one year A year ago, Beida looked around for today's famous VC and PE, but no one paid attention to it, and finally only entered in courtesy So you have to laugh, countless PE are staring at those high-quality drug companies that are going to be listed, and such behavior of collecting money is really something even a fool knows to do Ask: does a company that doesn't need money need such capital? Does the development of Chinese pharmaceutical industry need such capital? Where does such capital contribute to the development of China's pharmaceutical industry? How many pharmaceutical enterprises are similar to Beida one year ago and two years ago? When these innovative enterprises are still in the early stage and in urgent need of capital promotion, they can't find VC in the Chinese pharmaceutical industry There is no venture capital in China Pharmaceutical Where is the investment and financing environment of Chinese pharmaceutical industry superior to the past? Where is the progress? The third is the lack of model entrepreneurs and managers in China's pharmaceutical industry For today's Chinese public society, you can count the heavyweight entrepreneurs with your eyes closed, but you can't count the entrepreneurs in the pharmaceutical industry Usually we would say that the size of pharmaceutical enterprises is too small compared with other industries, but this is absolutely an excuse A large number of Internet enterprises have long-term losses, and the profits of pharmaceutical enterprises are unmatched by other industries The key reason lies in how many ideas and values pharmaceutical entrepreneurs export to the public, which is the core Low key is not the unique product of pharmaceutical entrepreneurs Ren Zhengfei never accepts media interviews, but his speech in the enterprise is regarded as the business standard as soon as it is published How many speeches can our pharmaceutical entrepreneurs leave that can be put on the medical history shelf? It's not eloquence, it's a summary of practical work, it's the distillation of ideas At the same time, professional managers in the pharmaceutical industry show intense agitation and mobility at present There have been research data and practical evidence that the compensation of senior managers in Chinese enterprises is close to the level of some developed countries However, from the perspective of data research, it's very frustrating to see how much leadership and management ability of these professional managers have improved and how much progress they have made: 60% of Chinese employees' commitment to work is lower than the global average level, and 15% of employees' commitment is high, but they can't work effectively and have a strong sense of frustration because they don't get the necessary support of the organization It's no surprise that there isn't a single pharmaceutical company on China Entrepreneur's recently released list of 20 best leadership development companies